Dear All: CARB-X have just announced their 2nd 2026 call for applications. There are 4 thematic areas for your proposals: Direct-acting therapeutics for infections caused
Dear All: Significantly strengthening our database documenting the human cost of AMR, we now have an impressive survey of mortality associated with severe infections in
17 Sep 2024 update: This is now the second of a 3-part newsletter series! See also part 1 (“#AMRSOS! GRAM report: ‘at least 1.27m deaths/year
Note: I’ve been away on holiday (see the newsletter’s postscript) and so there are multiple new items in both the meetings calendar and the list
Dear All (and with thanks to Lucy Naga for being the lead author on this economic-focused newsletter), Antimicrobials are the quiet safety net of modern
Dear All: An important and instructive analysis of optimal global antibiotic usage targets has just been published in Lancet Public Health. To follow the plot,
Dear All (and with thanks to Aaron Dane for co-authoring this newsletter AND inhale, exhale … this is going to be a long, wonkish, but VERY
Dear All: WHO have announced a very interesting 2-h virtual dialogue on optimal evidence generation across the antibiotic R&D lifecycle! Here are the details you
Dear All: Two important webinars have just been announced! 22 July (virtual, 2-3.30p CET): The WHO AMR Department and the WHO GAP-r (Global Accelerator for
Dear All: Both FDA and EMA have very recently released important documents for comment. See below the links and commentary on the two documents. ==